The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Completed · Phase 1

Conditions studied: Urinary Bladder, Overactive

In brief

This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.

Key facts

Study ID

NCT00914667

Run by

Pfizer

People needed

14

Starts

2009-07-01

Expected to finish

2009-08-01

Last updated by the study team

2011-06-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects between the ages of 18 and 55 years

You may not qualify if…

• Not healthy subjects--subjects with acute or chronic medical or psychiatric conditions or laboratory abnormality

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.